Legacy Wealth Asset Management LLC Acquires 1,581 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Legacy Wealth Asset Management LLC raised its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 19.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,509 shares of the medical equipment provider’s stock after purchasing an additional 1,581 shares during the quarter. Legacy Wealth Asset Management LLC’s holdings in Lantheus were worth $592,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Tucker Asset Management LLC raised its position in Lantheus by 239.0% in the third quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 282 shares during the period. Principal Securities Inc. bought a new stake in Lantheus in the 4th quarter worth $28,000. NBC Securities Inc. increased its position in shares of Lantheus by 28.4% in the first quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider’s stock valued at $53,000 after acquiring an additional 191 shares during the period. First Horizon Advisors Inc. increased its holdings in Lantheus by 103.9% during the 4th quarter. First Horizon Advisors Inc. now owns 932 shares of the medical equipment provider’s stock valued at $58,000 after purchasing an additional 475 shares during the period. Finally, Quest Partners LLC purchased a new stake in Lantheus in the 4th quarter worth approximately $101,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on LNTH. B. Riley increased their target price on Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research note on Thursday, April 18th. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Friday, May 3rd. Truist Financial lifted their target price on Lantheus from $82.00 to $96.00 and gave the stock a “buy” rating in a report on Friday, May 3rd. Finally, Mizuho increased their price objective on Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, May 3rd. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $99.17.

Lantheus Trading Up 1.4 %

NASDAQ:LNTH opened at $79.56 on Friday. The firm has a market capitalization of $5.51 billion, a price-to-earnings ratio of 12.15 and a beta of 0.51. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.84 and a quick ratio of 4.55. The business has a fifty day moving average price of $78.60 and a 200-day moving average price of $66.15. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $91.81.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.51 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.11. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. The company had revenue of $369.98 million for the quarter, compared to analysts’ expectations of $349.46 million. Sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.46 EPS for the current year.

Insiders Place Their Bets

In other Lantheus news, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction dated Thursday, June 13th. The shares were sold at an average price of $79.77, for a total value of $27,201.57. Following the transaction, the chief accounting officer now directly owns 62,557 shares in the company, valued at approximately $4,990,171.89. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Lantheus news, insider Daniel Niedzwiecki sold 12,873 shares of the firm’s stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $79.86, for a total value of $1,028,037.78. Following the completion of the sale, the insider now owns 80,244 shares of the company’s stock, valued at $6,408,285.84. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CAO Andrea Sabens sold 341 shares of the firm’s stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $79.77, for a total transaction of $27,201.57. Following the completion of the transaction, the chief accounting officer now directly owns 62,557 shares of the company’s stock, valued at approximately $4,990,171.89. The disclosure for this sale can be found here. Insiders have sold a total of 32,269 shares of company stock worth $2,557,300 over the last quarter. Company insiders own 2.10% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.